表紙:アルツハイマー病治療・診断:世界市場
市場調査レポート
商品コード
974122

アルツハイマー病治療・診断:世界市場

Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

出版日: | 発行: BCC Research | ページ情報: 英文 88 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.03円
アルツハイマー病治療・診断:世界市場
出版日: 2020年11月27日
発行: BCC Research
ページ情報: 英文 88 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界におけるアルツハイマー病治療の市場規模は、2020年の48億米ドルから2025年までに63億米ドルに成長し、2020年から2025年間のCAGRは5.5%が見込まれています。

北米におけるアルツハイマー病治療の市場規模は、2020年の25億米ドルから2025年までに33億米ドルに成長し、2020年から2025年間のCAGRは5.6%が見込まれています。

アジア太平洋におけるアルツハイマー病治療の市場規模は2020年の13億米ドルから2025年までに17億米ドルに成長し、2020年から2025年間のCAGRは5.6%が見込まれています。

当レポートでは、世界のアルツハイマー病治療・診断市場について包括的に調査し、市場規模・予測、市場機会、主要国/地域およびセグメント別による市場分析と予測、および主要企業のプロファイルなどを提供しています。

目次

第1章 イントロダクション

  • 調査目標・目的
  • 本調査の実施理由
  • レポートの範囲
  • 情報源
  • 調査手法
  • アナリストの経歴
  • BCCカスタム調査
  • BCC Research の関連レポート

第2章 サマリーとハイライト

第3章 概要

  • アルツハイマー病:定義と市場構造
  • アルツハイマー病の病態生理学
  • ADとアミロイドカスケード
  • ADとタウオパチー
  • ADおよび神経伝達物質システム
  • アルツハイマー病の病因
  • 遺伝的要因
  • 非遺伝的要因
  • アルツハイマー病の疫学
  • 発症年齢
  • 発生率、有病率および死亡率
  • ADの段階と重症度
  • 併存症
  • アルツハイマー病の診断と治療
  • アルツハイマー病の診断
  • AS向けコンパニオンイメージング診断
  • アミロイド可視化のためのCIDX技術
  • TAU-NFT視覚化のためのCIDX技術
  • 開発中のタウトレーサーの比較分析
  • CIDX技術:AB対タウイメージング技術
  • 結論
  • ADの薬物治療

第4章 規制構造

  • 米国
  • 承認の加速
  • ファストトラック指定
  • 画期的治療薬の指定
  • 優先審査
  • 規制物質法
  • 特別プロトコル評価
  • 新しい監視と安全の要件
  • カナダ
  • メキシコ
  • 欧州
  • アジア太平洋
  • その他の地域
  • 償還情勢

第5章 市場力学

  • 市場成長促進要因
  • 診断および医薬品開発におけるバイオマーカーの使用
  • パイプラインにおける多数の薬剤
  • 市場の抑制要因
  • ブランド医薬品の特許満了とジェネリック医薬品の出現
  • 医薬品開発における高い失敗率
  • 医薬品開発の高コスト

第6章 アルツハイマー病治療薬の世界市場

  • 市場概要
  • 世界のアルツハイマー病治療薬市場:作用機序別
  • アセチルコリンエステラーゼ阻害剤(AChEI)
  • NMDAドラッグ
  • 世界のブランド/ジェネリックAD治療薬市場:タイプ別
  • 世界のAD治療薬市場:AD段階別

第7章 市場内訳:地域別

  • 世界市場:地域別
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域
  • 業界構造
  • 一般的なAD治療薬の影響

第8章 パイプライン分析

  • 医薬品開発プロセスの概要
  • フェーズIII
  • フェーズII
  • フェーズI
  • 治験依頼者

第9章 企業プロファイル

  • ABBVIE
  • ACADIA PHARMACEUTICALS INC.
  • ALEMBIC PHARMACEUTICALS LTD.
  • ALEXZA PHARMACEUTICALS
  • ALKERMES PLC
  • ALLERGAN PLC
  • APOTEX INC.
  • ASTRAZENECA PLC
  • AUROBINDO PHARMA
  • AVANIR PHARMACEUTICALS INC.
  • BOEHRINGER INGELHEIM
  • BRISTOL-MYERS SQUIBB CO.
  • BIOGEN
  • DAIICHI SANKYO CO., LTD.
  • DR. REDDY'S LABORATORIES LTD.
  • ELI LILLY AND CO.
  • EISAI CO., LTD.
  • F. HOFFMANN-LA ROCHE AG
  • GLAXOSMITHKLINE PLC
  • GEDEON RICHTER PLC
  • IMMUNOCELLULAR THERAPEUTICS LTD.
  • JOHNSON & JOHNSON
  • LANNETT CO., INC.
  • H. LUNDBECK A/S
  • LUPIN LTD.
  • MALLINCKRODT
  • MERCK & CO.
  • MYLAN NV
  • NEXTSOURCE BIOTECHNOLOGY LLC
  • NOVARTIS AG
  • OTSUKA HOLDINGS CO., LTD.
  • PFIZER INC.
  • SANOFI
  • SUMITOMO DAINIPPON PHARMA CO., LTD.
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • TORRENT PHARMACEUTICALS LTD.
  • UCB SA

第10章 付録:頭字語

図表

List of Tables

  • Summary Table : Global Market for Alzheimer's Drugs, by Region, Through 2025
  • Table 1 : Alzheimer's Patients and Cost of Care for AD in the U.S., 2015-2030
  • Table 2 : Pharmacological Treatment of BPSD of Alzheimer's
  • Table 3 : Computerized Screening Tests Used in Detecting Cognitive Impairment
  • Table 4 : Brain Imaging Technologies and Application in the Alzheimer's Context
  • Table 5 : Global Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
  • Table 6 : Global Market for Alzheimer's AChEIs Drugs, by Region, Through 2025
  • Table 7 : Global Market for Alzheimer's NMDA Drugs , by Region, Through 2025
  • Table 8 : Global Market for Alzheimer's Drugs, by Type, Through 2025
  • Table 9 : Global Market for AD Therapeutics, by Disease Stage, Through 2025
  • Table 10 : Global Market for Late Stage/Severe AD Therapeutics, by Region, Through 2025
  • Table 11 : Global Market for Early/Middle Stage AD Therapeutics, by Region, Through 2025
  • Table 12 : Global Market for Alzheimer's Drugs, by Region, Through 2025
  • Table 13 : North American Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
  • Table 14 : North American Market for Alzheimer's Drugs, by Country, Through 2025
  • Table 15 : North American Market for Alzheimer's Drugs, by Type, Through 2025
  • Table 16 : European Market for Alzheimer's Drugs, by Country, Through 2025
  • Table 17 : European Market for Alzheimer's Drugs, by Type, Through 2025
  • Table 18 : European Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
  • Table 19 : Asia-Pacific Market for Alzheimer's Drugs, by Type, Through 2025
  • Table 20 : Asia-Pacific Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
  • Table 21 : Global Ranking of Leading Players in Alzheimer's Disease Drugs
  • Table 22 : Agents in Phase III of Alzheimer's Disease Drug Development
  • Table 23 : Agents in Phase II of Alzheimer's Disease Drug Development
  • Table 24 : Agents in Phase I of Alzheimer's Disease Drug Development
  • Table 25 : Trial Sponsor for Each Phase of Alzheimer's Disease Drug Development
  • Table 26 : Acronyms Used in This Report

List of Figures

  • Summary Figure : Global Market Shares of Alzheimer's Drugs, by Region, 2019
  • Figure 1 : Trends in Alzheimer's Patients and Cost of Care for AD in the U.S., 2015-2030
  • Figure 2 : Pharmaceutical Regulatory Pathways in the U.S. and Europe
  • Figure 3 : Global Market for Alzheimer's AChEIs Drugs, 2019-2025
  • Figure 4 : Global Market for Alzheimer's NMDA Drugs, 2019-2025
  • Figure 5 : Global Market Shares of Alzheimer's Drugs, by Region, 2019
  • Figure 6 : North American Market for Alzheimer's Drugs, 2019-2025
  • Figure 7 : European Market for Alzheimer's Drugs, 2019-2025
  • Figure 8 : Asia-Pacific Market for Alzheimer's Drugs, 2019-2025
  • Figure 9 : South American Market for Alzheimer's Drugs, 2019-2025
  • Figure 10 : Middle Eastern and African Market for Alzheimer's Drugs, 2019-2025
目次
Product Code: PHM062D

Highlights:

The global market for Alzheimer’s disease treatment should grow from $4.8 billion in 2020 to $6.3 billion by 2025 with a compound annual growth rate (CAGR) of 5.5% during the period of 2020-2025.

The North American market for Alzheimer’s disease treatment should grow from $2.5 billion in 2020 to $3.3 billion by 2025 with a CAGR of 5.6% during the period of 2020-2025.

The Asia-Pacific market for Alzheimer’s disease treatment should grow from $1.3 billion in 2020 to $1.7 billion by 2025 with a CAGR of 5.6% during the period of 2020-2025.

Report Scope:

The scope of this study encompasses the global and regional markets for Alzheimer's therapeutics and diagnostics. These markets are segmented by branded and generic drugs, and mechanism of action, such as acetylcholine inhibitors (AChEIs) and N-methyl-D-aspartate (NMDA) receptor antagonists, a combination drug of donepezil and memantine, tau aggregation inhibitors (TAI) and amyloid-beta (AB) vaccines. Drugs are also segmented by the stage of Alzheimer's disease they treat, i.e., mild to moderate, severe and prodromal.

BCC Research analyzed each market and its applications, regulatory environment, assistive technologies, market projections and market share. Issues discussed include the major drug profiles, clinical groundwork, technological features and trends. The regional markets for AD therapeutics and diagnostics include selected markets in the U.S., Canada, the U.K., France, Germany, Italy, Spain, Japan, China and India. These markets are grouped as North America, Europe, Asia-Pacific and Rest of the world (RoW).

Report Includes:

  • 27 tables
  • An overview of the global market for Alzheimer's disease (AD) therapeutics and diagnostics
  • Estimation of the market size and analyses of global market trends with data from 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025
  • Detailed description of Alzheimer's disease and discussion on disease-related events, etiology and epidemiology covering prevalence and incidence rates
  • Identification of diagnostic tools and equipment; evaluation of important scientific and technological frameworks; and coverage of developments in the global market for Alzheimer's disease therapeutics and diagnostics.
  • Information on products that are currently available for the diagnosis and treatment of Alzheimer's disease as well as highlights of the promising new drug candidates and diagnostic imaging agents
  • Market share analysis of Alzheimer's disease therapeutics and diagnostics, by mechanism of action, disease stage and major geographical regions covering North America, Europe, APAC and Rest of the World
  • Detailed analysis of the current market trends, market forecast, drivers, challenges, and opportunities affecting market growth and discussion on regulatory and competitive elements that are affecting the future marketplace
  • Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
  • Company profiles of major market players, including AbbVie, AstraZeneca Plc, Bristol-Myers Squibb, Eli Lilly and Co., F. Hoffmann-La Roche AG, GlaxoSmithKline, Johnson & Johnson, Pfizer Inc., Novartis and Sanofi

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing this Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Overview

  • Alzheimer's Disease: Definition and Market Structure
  • Alzheimer's Disease Pathophysiology
  • AD and Amyloid Cascade
  • AD and Tauopathy
  • AD and Neurotransmitter Systems
  • Alzheimer's Disease Etiology
  • Genetic Factors
  • Non-Genetic Factors
  • Alzheimer's Disease Epidemiology
  • Age of Onset
  • Incidence, Prevalence and Mortality
  • Stages and Severity of AD
  • Comorbidities
  • Diagnosis and Treatment of Alzheimer's
  • Diagnosis of Alzheimer's
  • Companion Imaging Diagnostics for AS
  • CIDX Technologies for Amyloid Visualization
  • CIDX Technologies for TAU-NFT Visualization
  • Comparative Analysis of Tau Tracers in Development
  • CIDX Technologies: AB vs. Tau Imaging Technologies
  • Concluding Remarks
  • Pharmaceutical Treatment of AD

Chapter 4 Regulatory Structure

  • U.S.
  • Accelerated Approvals
  • Fast Track Designation
  • Breakthrough Therapy Designation
  • Priority Review
  • Controlled Substances Act
  • Special Protocol Assessments
  • New Surveillance and Safety Requirements
  • Canada
  • Mexico
  • Europe
  • Asia-Pacific
  • Rest of the World
  • Reimbursement Landscape

Chapter 5 Market Dynamics

  • Market Drivers
  • Use of Biomarkers in Diagnosis and Drug Development
  • Large Number of Drugs in the Pipeline
  • Market Restraints
  • Patent Expirations of Branded Drugs and Emergence of Generics
  • High Failure Rate in Drug Development
  • High Cost of Drug Development

Chapter 6 Global Markets for Alzheimer's Disease Therapeutics

  • Market Overview
  • Global Market for Alzheimer's Drugs by Mechanism of Action
  • Acetylcholinesterase Inhibitors (AChEIs)
  • NMDA Drugs
  • Global Market for Branded/Generic AD Therapeutics by Type
  • Global Market for AD Therapeutics by Stage of AD

Chapter 7 Market Breakdown by Region

  • Global Market for Alzheimer's Drugs by Region
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
  • Industry Structure
  • Impact of Generic AD Therapeutics

Chapter 8 Pipeline Analysis

  • Overview of the Drug Development Process
  • Phase III
  • Phase II
  • Phase I
  • Trial Sponsors

Chapter 9 Company Profiles

  • ABBVIE
  • ACADIA PHARMACEUTICALS INC.
  • ALEMBIC PHARMACEUTICALS LTD.
  • ALEXZA PHARMACEUTICALS
  • ALKERMES PLC
  • ALLERGAN PLC
  • APOTEX INC.
  • ASTRAZENECA PLC
  • AUROBINDO PHARMA
  • AVANIR PHARMACEUTICALS INC.
  • BOEHRINGER INGELHEIM
  • BRISTOL-MYERS SQUIBB CO.
  • BIOGEN
  • DAIICHI SANKYO CO., LTD.
  • DR. REDDY'S LABORATORIES LTD.
  • ELI LILLY AND CO.
  • EISAI CO., LTD.
  • F. HOFFMANN-LA ROCHE AG
  • GLAXOSMITHKLINE PLC
  • GEDEON RICHTER PLC
  • IMMUNOCELLULAR THERAPEUTICS LTD.
  • JOHNSON & JOHNSON
  • LANNETT CO., INC.
  • H. LUNDBECK A/S
  • LUPIN LTD.
  • MALLINCKRODT
  • MERCK & CO.
  • MYLAN NV
  • NEXTSOURCE BIOTECHNOLOGY LLC
  • NOVARTIS AG
  • OTSUKA HOLDINGS CO., LTD.
  • PFIZER INC.
  • SANOFI
  • SUMITOMO DAINIPPON PHARMA CO., LTD.
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • TORRENT PHARMACEUTICALS LTD.
  • UCB SA

Chapter 10 Appendix: Acronyms